IndraLab
Statements
reach
"These data are consistent with those of XREF_BIBR) for both patient survival based on the BAP1 mutational status (32 vs 133 months for BAP1 mutation positive vs BAP1 mutation negative tumours) or BAP1 protein expression (31 vs 133 months for tumours showing negative BAP1 expression by IHC vs those with positive BAP1 expression) and thus the proposed role of BAP1 in the pathogenesis of UM with an aggressive phenotype."
reach
"Our observation that a greater number of tumors exhibited loss of BAP1 protein expression by IHC compared with BAP1 deletions or mutations indicates that BAP1 may become functionally inactivated by mechanisms other than deletions or mutations in the coding region; for example, epigenetic changes leading to silencing of the BAP1 gene or other, yet to be identified, alterations that prevent BAP1 expression."
reach
"Recently, loss of BAP1 (BRCA1-associated protein-1) expression by IHC, homozygous deletion of CDKN2A (p16) by FISH, and expression of methyl-thio-adenosine phosphorylase (MTAP) by IHC were added as markers to distinguish non-neoplastic from neoplastic cells when mesothelial proliferation is confined to the serosal surface."
reach
"We previously demonstrated that BAP1 and PBRM1 expression by immunohistochemistry (IHC) are highly correlated with mutation status (P = 3E-58 and 4E-23 respectively 34 and that BAP1 and PBRM1 expression by IHC are independent predictors of both disease-free survival and overall survival in the localized disease setting."